HCmed Takes Milestone in Development of Combination Immunoglobin Products with CSL Behring
Posted: October 24, 2021 at 8:00 p.m. CDT|Update: 51 minutes ago
TAIPEI, 24 October 2021 / PRNewswire / – HCmed Innovations (HCmed), a Taiwanese company focused on the development of vibrating mesh nebulizers, today announced the successful completion of the first stage of development of the collaboration agreement with CSL Behring.
Earlier this year, world leader in biotherapy CSL Behring partnered with HCmed to develop a combination product consisting of a formulation of plasma-derived immunoglobulin (CSL787) delivered via a customized version of the AdheResp nebulizer, the mesh nebulizer actuated by HCmed breathing. As HCmed has now completed development of the custom device to meet aerosol performance requirements, HCmed will receive the first milestone payment from the partnership. This is a significant achievement for HCmed’s new respiratory actuation platform, AdheResp, which proves that HCmed’s mesh platform is fully capable of delivering biologics via an airway with superior quality. and affordable cost.
Inhaled forms of immunoglobulins will potentially diversify delivery options, and because nebulization therapy can be self-administered by patients, demands on healthcare resources can also be alleviated. In addition, with the breath-actuated nebulizers brought to the collaboration, the way in which future patients receive inhalation treatments is expected to gradually change. With this feature, nebulizers generate aerosols only in response to a patient’s inhalation, thus reducing drug loss during exhalation. This feature makes breath-actuated nebulizers a more desirable device for aerosolizing high value therapeutic drugs.
“This represents another step forward in the development of new mesh nebulizers for easier delivery of plasma-derived immunoglobulins., “ said the CEO of HCmed Jason cheng. “With CSL Behring, we are committed to to supply affordable and effective treatment options for patients with respiratory diseases, and this step brings us closer to our goal. “
Founded in 2014, HCmed Innovations Co., Ltd. (HCmed) is focused on developing drug-device combination products based on its vibrating mesh nebulizer technology. The company is backed by funds from Vivo Capital and other major US investors, Taiwan, and Japan. Its medical devices have successfully received several regulatory approvals, such as US FDA, European CE, Taiwan TFDA, Brazilian Anvisa, Indonesian Badan POM and China NMPA. HCmed’s mesh nebulizers were launched in Brazil and China. The vision is to bring significant value to global pharmaceutical partners through a cost-effective and risk-minimized route, by designing combination products that can make great contributions in the respiratory field. For more information on HCmed, please visit www.hcmed-inno.com.
Show original content:
SOURCE HCmed Innovations Co., Ltd.
The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.